Skip to main content
. 2021 Jan 12;10(1):144. doi: 10.3390/cells10010144

Figure 2.

Figure 2

CDK8/19 inhibitors senexin B (SNXB) and 15w prevent resistance to EGFR inhibitor gefitinib (GEF) in SKBR3 breast cancer cells. (A). Representative photographs showing cell density (crystal violet staining) in flasks at 4, 8 and 10 weeks of treatment. (B). Representative phase-contrast microphotographs at 3 days, and at 1, 2, 3, 4, 8 and 10 weeks of treatment. (C). Densitometric measurements of photomicrographs expressed as percentage of cell density in DMSO controls at 2 weeks. Data shown as mean (n = 4 images/flask) ± SEM. p < 0.0001 for GEF vs. GEF+SNXB/15w (*) at 8 weeks.